And those two elements are rare to find in biopharmaceutical companies, particularly of our current size. So on the financial here and now, we have assembled based on our technologies, which are, I think fairly easily understood, now they are quite advanced.We have a pipeline or portfolio of five major commercial products and these are commercial products approved in markets around the world. Five products that are almost all of them early in their commercial life with long patent protection, patent protections 20s for the most part.
Alkermes' CEO Presents At Morgan Stanley Global Healthcare Conference (Transcript)
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts